Updates are available Correction dated 2025-04-09
Click to view Correction: https://doi.org/10.1186/s13046-025-03384-w
-
Authors
Cortés-Hernández, Luis Enrique
Eslami-S, Zahra
Attina, Aurore
Batista, Silvia
Cayrefourcq, Laure
Vialeret, Jérôme
Di Vizio, Dolores
Hirtz, Christophe
Costa-Silva, Bruno
Alix-Panabières, Catherine
-
Funding
Funding for this research was provided by:
Horizon 2020 (765492, 765492, 765492, 765492)
National Institutes of Health (R01CA234557)
Nationals Institutes of Health (R01CA287075)
European Molecular Biology Organization (3921)
Pfizer, Breast Cancer Now’s Catalyst Programme (2017NovPCC1058)
Fundación Bancaria Caixa d'Estalvis i Pensions de Barcelona (LCF/PR/HR19/52160014)
Institut National Du Cancer (INCa_Inserm_DGOS_12553)
European Union, Horizon 2020, ERA-NET TRASNCAN (964264)
Fondation ARC
- License Information
-
More Information
Article History
Received: 23 January 2025
Accepted: 9 March 2025
First Online: 22 March 2025
Change Date: 9 April 2025
Change Type: Update
Change Details: The original online version of this article was revised: the authors identified an error in Figure 2.
Change Date: 9 April 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13046-025-03384-w
Declarations
:
: All animal experiments were performed after approval by the Champalimaud Foundation Animal Welfare Body (Protocol number 2017/006).
: Not applicable.
: Catherine Alix-Panabières is one of the patent holders (US Patent Number 16,093,934) for detecting and/or characterizing circulating tumor cells. The remaining authors declare that they have no conflicts of interest.
